Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MCT101 FL
- Development stage
- Preclinical
- Lead developer
- Metacen Therapeutics
01
Overview
MCT101 FL is a preclinical drug candidate being developed by Metacen Therapeutics for the treatment of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). The asset is part of Metacen's research pipeline, which utilizes proprietary technology platforms such as FAT Tech, aimed at the reduction of Advanced Glycation End-products (AGEs). AGEs are metabolic byproducts associated with inflammation and oxidative stress in metabolic liver diseases. As of early 2024, MCT101 FL remains in the research/preclinical stage, and its specific molecular target, modality, and route of administration have not been publicly disclosed.
Beyond the preview
Go deeper on MCT101 FL.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MCT101 FL.